Trevi Therapeutics completed a $162 million stock offering, extending its cash runway into 2030 to support ongoing development of Haduvio for chronic cough related to IPF, non-IPF ILD, and refractory chronic cough. The company plans to initiate multiple clinical trials in 2026, including Phase 3 trials for IPF-related chronic cough and Phase 2b trials for RCC and non-IPF ILD-related cough. With recent FDA alignment and a new European patent, Trevi is positioned to advance toward potential FDA approval. Financially, the company reported a net loss of $13.2 million for Q1 2026, with increased R&D and administrative expenses reflecting clinical progress.
Zoom Video Communications has appointed Carlos Quaderi as Head of Asia Pacific (APAC), effective August 1, 2026. Quaderi will oversee Zoom's go-to-market strategy across APAC, including Australia, New Zealand, Asia, India, and Korea (excluding Japan)...
FDH Aero and LATECOERE have entered a global supply agreement, making FDH Hardware a key supplier for LATECOERE's manufacturing sites in Brazil, Bulgaria, France, the Czech Republic, Tunisia, and Morocco. This partnership aligns FDH Aero's hardware p...
YieldMax ETFs announced weekly distributions for its Group 1 option income ETFs, with payments scheduled for July 23, 2026. The distributions vary by ETF, with rates ranging from about 26% to over 60% annualized based on recent NAV, reflecting income...
BioNTech SE will announce its second quarter 2026 financial results on August 4, 2026, followed by a webcast and conference call for investors and the public. The event will cover financial performance and updates on BioNTech's oncology pipeline, whi...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group plc, disclosed its share dealings on July 20, 2026. The bank purchased 1,786,258 ordinary shares and sold 1,952,322 ordinary shares at prices around 279 to 280 ...
